Synchronized Cardioversion for Hemodynamically Stable Monomorphic Ventricular Tachycardia
For hemodynamically stable monomorphic VT, synchronized electrical cardioversion with 100 J is the most effective first-line treatment and should be performed after brief sedation or anesthesia. 1
Pre-Cardioversion Steps
Confirm the Diagnosis
- Obtain a 12-lead ECG immediately to confirm monomorphic VT and exclude supraventricular tachycardia with aberrancy 1, 2
- Look for diagnostic features: QRS width >0.14 seconds with RBBB pattern or >0.16 seconds with LBBB pattern, AV dissociation, fusion or capture beats, and RS interval >100 ms in any precordial lead 1
- When uncertain whether the rhythm is VT or SVT with aberrancy, always treat as VT to avoid the catastrophic risk of undertreatment 1
Verify Hemodynamic Stability
- Confirm the patient has systolic blood pressure ≥90 mmHg, normal mental status, no chest pain, no pulmonary edema, and no signs of shock 1, 3
- If any signs of instability are present (hypotension, altered mental status, chest pain, acute heart failure, or shock), proceed immediately to cardioversion without delay 1, 3
Prepare Equipment and Monitoring
- Ensure continuous cardiac monitoring, pulse oximetry, and blood pressure monitoring are in place 3
- Have resuscitation equipment immediately available, including a defibrillator, airway management supplies, and emergency medications, as cardioversion may occasionally induce ventricular fibrillation or asystole 3
- Establish secure intravenous access 3
Cardioversion Procedure
Sedation
- Administer brief anesthesia or procedural sedation when the patient's hemodynamic status permits 1
- Common agents include midazolam, propofol, or etomidate, titrated to effect 1
Energy Selection and Delivery
- Set the defibrillator to synchronized mode to ensure the shock is delivered on the R-wave peak, never on the T-wave, which could precipitate ventricular fibrillation 3
- Deliver an initial synchronized shock of 100 J for monomorphic VT with rates >150 bpm 1, 2
- Verify that synchronization markers appear on each QRS complex before delivering the shock 3
If First Shock Fails
- If the initial 100 J shock is unsuccessful, escalate energy sequentially: 200 J, then 300 J, then 360 J 1
- Do not delay with additional pharmacologic therapy; escalate the energy instead 1
- For refractory cases after standard escalation, double sequential synchronized cardioversion may be considered as a rescue technique 4
Post-Cardioversion Management
Immediate Monitoring
- Monitor closely for atrial or ventricular premature complexes immediately after cardioversion, as these may trigger recurrent VT 5, 3
- Watch for transient depression of myocardial function, particularly after repeated shocks or higher energies 3
Prevention of Recurrence
- If VT recurs after successful cardioversion, administer intravenous antiarrhythmic therapy to prevent acute reinitiation 1, 3
- For patients without severe heart failure or acute MI, intravenous procainamide (10 mg/kg at 50-100 mg/min over 10-20 minutes) is the preferred agent 1, 2
- For patients with heart failure, suspected ischemia, or left ventricular ejection fraction ≤40%, intravenous amiodarone is preferred over procainamide 1, 2
Critical Safety Pitfalls
Medications to Avoid
- Never administer calcium-channel blockers (verapamil, diltiazem) for wide-complex tachycardia in structural heart disease, as they can precipitate ventricular fibrillation and hemodynamic collapse 1, 3
- The only exception is confirmed left-ventricular fascicular VT (RBBB morphology with left axis deviation), where verapamil or β-blockers are safe 1, 2
Synchronization Errors
- Always verify proper synchronization before each shock delivery 3
- Failure to synchronize may result in shock-on-T phenomenon and degeneration to ventricular fibrillation 3
Delaying Cardioversion
- Do not delay cardioversion in favor of prolonged pharmacologic trials, as electrical cardioversion is more effective than any medication 1
- Even after amiodarone loading, proceed directly to cardioversion rather than waiting for drug effect, which requires 20-30 minutes and offers no additional benefit 1